The Nak. isoantigen is expressed on glycoprotein (GP) IV (CD36). a platelet membrane GP that has been identified as having a role in platelet interactions with collagen and thrombospondin and in binding Plasmodium felciparuminfected erythrocytes to endothelial cells and melanoma cells. We have studied normal platelets and Nak" platelets from two Japanese donors that have 1% of GPIV by concentration-dependent antibody binding and flow cytometry. We studied the adherence of normal and Nak"-platelets to types 1,111, and IV collagen in static and to type I collagen in flowing systems a t high shear force. We have also studied aggregation of normal and Nak"-platelets to type I collagen. Nakeplatelets showed normal or increased aggregation to type N 1989, IKEDA and colleagues defined a new platelet isoantigen, Nak", in a thrombocytopenic patient who was refractory to transfusions of HLA-matched platelets.' Family studies showed that the Nak" antigen was inherited as an autosomal codominant trait. The frequency in the Japanese population of the Nak" antigen is between 89% and 97%'.' and is greater than 99% in the US population.' Ikeda reported that the Nak" epitope did not reside on glycoprotein (GP) IIb-IIIa, GPIb, or HLA class I.' Tomiyama et a13 provided evidence that the Nak" isoantigen is located on CPIV, also known as GPIIIb, a major platelet membrane receptor that is identical to the CD36 differentiation antigen. GPIV is found on platelets, monocytes, some endothelial cells, B lymphocytes, and erythrocytes infected with Plasmodium falciparum. Platelet GPIV has been identified as a site for thrombospondin binding$5 as playing a role in binding P fakiparum-infected erythrocytes to endothelial cells and melanoma and as a GP involved in platelet adhesion to collagen.* The adhesion of platelets to collagen plays a major role in hemostasis and thrombosis. When vascular endothelium is disrupted, platelets adhere to subendothelial collagen that causes shape change and secretion of the contents of their Q and dense granules, resulting in platelet aggregation and the formation of a hemostatic plug. Several proteins have been proposed as platelet surface receptors for collagen; they include (1) GPIIb,9 (2) GPIIb-IIIa complex,'O~" (3) GPIaIIa," (4) GPIa," ( 5 ) GPIb,14 (6) a 65-kD p r~t e i n , '~ We also studied endogenous thrombospondin surface expression and found that thrombin-stimulated Nak" platelets expressed the same amount of thrombospondin as did normal platelets. From our studies with Nak"-platelets, we cannot identify a definitive role for GPIV in platelet aggregation, in adhesion to types 1,111, and IV collagen, or in endogenous thrombospondin binding to platelets. This is a US government work. There are no restrictions on its use.
N 1989, IKEDA and colleagues defined a new platelet isoantigen, Nak", in a thrombocytopenic patient who was refractory to transfusions of HLA-matched platelets.' Family studies showed that the Nak" antigen was inherited as an autosomal codominant trait. The frequency in the Japanese population of the Nak" antigen is between 89% and 97%'.' and is greater than 99% in the US population.' Ikeda reported that the Nak" epitope did not reside on glycoprotein (GP) IIb-IIIa, GPIb, or HLA class I.' Tomiyama et a13 provided evidence that the Nak" isoantigen is located on CPIV, also known as GPIIIb, a major platelet membrane receptor that is identical to the CD36 differentiation antigen. GPIV is found on platelets, monocytes, some endothelial cells, B lymphocytes, and erythrocytes infected with Plasmodium falciparum. Platelet GPIV has been identified as a site for thrombospondin binding$5 as playing a role in binding P fakiparum-infected erythrocytes to endothelial cells and melanoma and as a GP involved in platelet adhesion to collagen.* The adhesion of platelets to collagen plays a major role in hemostasis and thrombosis. When vascular endothelium is disrupted, platelets adhere to subendothelial collagen that causes shape change and secretion of the contents of their Q and dense granules, resulting in platelet aggregation and the formation of a hemostatic plug. Several proteins have been proposed as platelet surface receptors for collagen; they include (1) GPIIb,9 (2) GPIIb-IIIa complex,'O~" (3) GPIaIIa," (4) GPIa," ( 5 ) GPIb,14 (6) a 65-kD p r~t e i n , '~ (7) a 75-kD polypeptide, 16 (8) an 80-kD p~lypeptide,'~ (9) fibronectin," (10) a platelet-collagen glucosyl transferase,'' and (1 1) GPIV.' Studies by Tandon et a1 suggested that GPIV mediated the early stages of platelet recognition by and initial attachment to collagen, but that there may be a second GPIVindependent mechanism that mediates the subsequent spreading and stabilization of adherent platelets such as the a2pI integrin also known as VLA-2 or GPIa-IIa.* In an attempt to identify the receptor(s) involved in collagen-platelet interactions, we have studied two Japanese women who are N&-, whose platelets have 2% of the normal complement of GPIV by flow cytometry and 1% by concentration-dependent antibody binding and normal platelet levels of It has been reported that Mg++ supports enhanced platelet adhesion to collagen and that Ca++ is inhibitory." We studied platelet adhesion from 0 to 60 minutes in the presence and absence of Mg++ and EDTA. We also studied the effects of normal and Nak"-platelet adhesion to collagen in the presence of monoclonal antibodies (MoAbs) directed against GPIV, thrombospondin, the a&, integrin, and GPIb.
MATERIALS AND METHODS
Collagen preparation. Type I collagen was isolated from commercial crude preparations of calf skin acid-soluble type I collagen (Sigma, St Louis, MO) by extraction in 0.5 mol/L acetic acid (HAC) at 4°C. The extracted material was precipitated by 4% NaCl and was redissolved in 0.5 molL HAC at 4°C. It was dialyzed for 24 hours against 0.02 moUL sodium phosphate, pH 9.0, until the pH of the retained material was 27.0. The precipitate was then collected by centrifugation at 4°C for 30 minutes at 7,50Og, redissolved in 0.1 m o a HAC, and dialyzed against 2 L of 0.1 mom HAC at 4°C with 6 changes. The collagen solution was lyophilized and frozen at -70°C until used. Before use, IO to 15 mg of the lyophilized collagen was dissolved in IO mL 5.0 mmol/L HAC by gentle mixing overnight at 4°C. It was centrifuged at 100,OOOg for 1 hour at 4°C and the collagen was stored at 4°C. The collagen was stable for 4 to 5 weeks at 4°C. The final preparation consisted solely of monomeric type I collagen. No noncollageneous protein was present as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSType I11 collagen from human fetal membrane and type IV collagen from human placenta (Calbiochem, San Diego, CA) were also used in platelet adhesion assays. When analyzed by SDS-PAGE, greater than 95% of the protein was type 111 or type IV collagen. bovine serum albumin (BSA) for 30 to 60 minutes at 25°C. The blocking buffer was aspirated, and the wells were washed 3 times with Tris buffer containing 0.9 mg/mL glucose, 5 mg/mL BSA, and 20 ng/mL prostaglandin E, (PGE,).
Platelets were drawn in acid citrate dextrose anticoagulant using a two syringe technique. Platelet-rich plasma (PRP) was prepared by centrifugation at 7508 for 3 minutes, and the red blood cells were washed once with Ringer's citrate dextrose buffer (RCD) with PGE,, pH 6.5. The platelets were pelleted by centrifugation for 12 minutes at 1,100g, then resuspended in the RCD buffer, pelleted again, and resuspended in RCD without PGE,. Platelets were labeled by the addition of 300 to 400 pCi of "'In oxyquinolone (Amersham, Arlington Heights, IL). After incubation at room temperature for 15 to 30 minutes, unbound "'In was removed by adding HEPES buffer containing PGE, and centrifuging at room temperature for 12 minutes at 1,100g. The labeled platelets were resuspended in HEPES without W E , and were counted. The final platelet concentration per well was 5 X 105 platelets. For some studies, the platelets were divided into 3 aliquots and were diluted in HEPES buffer without Mg or EDTA, in HEPES buffer with 1 0 0 pmol/L EDTA, or in HEPES buffer containing 2 mmoVL Mg". A total of 50 pL of platelet suspension were added to each collagen-coated well and were incubated for 4 to 60 minutes. After the appropriate incubation period, the plates were washed 3 times with the Tris buffer containing PGE,, glucose, and BSA. The wells were transferred to counting tubes and were counted in a gamma counter (Tracor, Elk Grove Village, IL).
We also performed adhesion experiments in the presence of the following MoAbs: OKM5, a gift of Ortho Diagnostics (Rariton, NJ), and 18568, which both recognize GPIV; 176D7, an antibody to the integrin complex; 181G8, an antibody to thrombospondin; and 125A7, an antibody to GPIb. In some experiments, after platelets were added to collagen-coated wells, the antibody 176D7 was added in the presence of Mg" to the wells and was allowed to incubate at room temperature for 1 to 29 minutes before washing the wells and counting the number of residual adherent platelets.
Platelet aggregation. Platelet aggregation studies were performed in a Chronolog Dual Channel Lumi-Aggregometer (Chronolog, Havertown, PA). Blood was drawn using a 2-syringe technique and was anticoagulated with 0.1 mL 3.8% sodium citrate per IO mL whole blood (final concentration, 10.9 mmol/L). PRP was prepared by centrifugation at 750g for 3 minutes at room temperature. The platelet count was adjusted to 200,OOO/pL by the addition of platelet poor plasma (PPP). PPP was prepared by centrifugation at 2,OOOg for 10 minutes at room temperature. Adenosine triphosphate (ATP) release was measured using luciferase-luciferin reagent (Sigma, St Louis, MO).
Flow cytometry. Flow cytometric analysis was performed on PRP and on Larex-(Consulting Associates, Inc. Tacoma, WA) purified platelets using an EPICS V flow cytometer (Coulter Electronics, Hialeah, FL) with a Coherent argon laser. Blood was obtained by venipuncture using a 2-syringe technique. The blood from the second syringe was placed into polypropylene tubes containing 0.1 mL of sodium citrate anticoagulant (final concentration, 10.9 mmol/L). PRP was prepared from whole blood by removal of the plasma layer after centrifugation at 750g for 3 minutes at 25°C. For preparation of Larex-purified platelets, the PRP was placed on a discontinuous gradient (3 mL of 20% and 5 mL of 10% Larex), and the platelets were separated from the plasma proteins by centrifugation at 2,OOOg for 30 minutes at 25°C as previously described.
The PFW or purified platelet preparation was diluted with Tyrodes buffer containing 1 mmol/L CaC1, to a concentration of 1.5 X lo*/ mL. The platelets were fixed with formaldehyde (final concentration, 1%) before incubation with MoAbs. One hundred-microliter aliquots of fixed platelets were mixed with 100 pL containing 0.5 pg of the monoclonal anti-GPIV antibodies OKM5 or 185G8. Log forward angle scatter (FALS) and log 90" light scatter (90LS) were used to gate the platelet population with exclusion of debris and rare mononuclear cells. A neutral density 1.3 filter was placed in front of the FALS detector. Single parameter 256-channel-gated log integral green fluorescent histograms were obtained, and negative and positive fluorescent populations were resolved. A three-decade log scale was used. The positive population was clearly resolved from the reagent control in terms of baseline separation, and the positive peak was directly integrated. A fluorescein isothiocyanate (FITC-labeled) antimouse F(ab'), fragment was used as the second antibody to detect positive platelets and as a negative control for the platelets not incubated with the murine MoAbs.
MoAb binding to platelets. Blood was drawn by a 2-syringe technique. The blood from the second syringe was placed in a polypropylene tube containing 10.9 mmoVL sodium citrate. The blood was centrifuged at 7508 for 3 minutes to obtain PRP. Platelets were purified from the PRP by centrifugation on a Larex gradient (3 mL 20% Larex and 5 mL 10% Larex). The platelets were diluted to 2 X IO*/mL in 0.145 m o m NaCI, 2.7 mmoVL KCI, 3.8 mmol/L HEPES, 0.1% glucose, 0.35% BSA, and 2 mmoVL CaCI2, pH 7.4.
The Fab fragment of MoAbs 18508 and OKM5, which recognize an 88-kD protein on normal platelets, was used to determine the number of GPIV molecules on normal and Nak" platelets. Concentration-dependent Fab binding to platelets was performed in the presence of EGTA or thrombin-activated platelets. Endogenous thrombospondin surface-expression studies were performed by incubation of 400 pL of nonactivated or thrombin-stimulated platelets with 100 pL of varying concentrations of a radiolabeled MoAb 18 1G8 specific for thrombospondin; binding was also performed in the presence of EGTA.
The MoAb Fab fragments were labeled with Na 1251 by the Pierce IODO-BEAD method (Pierce, Rockland, IL). The platelet-bound ' ' ' 1 MoAb was separated from free antibody by centrifugation on 1 mL of 10% Larex for 3 minutes at 12,000g. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From minutes to wash the vessel before blood perfusion. Citrated whole blood (final concentration, 10.9 mmoVL sodium citrate) was perfused and recirculated for 5 minutes at a rate of 300 mUmin at 37°C. The corresponding wall shear rate, 2,600 sec-', closely approximates conditions physiologically present in the microvasculature.
Crass sections of arterial segments were fixed, dehydrated, embedded in epoxy resin, and stained. Sections were evaluated morphometrically by light microscopy according to Baumgartner and Muggli.** Platelet-subendothelium interaction was categorized as C, contact platelets attached but not spread on the surface, or S, platelets spread on the surface. Platelet adhesion is defined as C + S, and each parameter is expressed as percentage of the total number of points counted (approximately 700) per vessel segment.
RESULTS
In platelet aggregation studies, the Nak"-patients had normal or decreased lag times, normal or enhanced total platelet aggregation, and normal ATP release to several doses of type I collagen (6.25 to 100 pg/mL. ; Fig 1) . The Naka-individuals also showed normal platelet aggregation and ATP release to other agonists including arachadonic acid, thrombin, ristocetin, adenosine diphosphate (ADP), and epinephrine.
Adhesion to BSA-coated wells was between 1% and 2% in normal and N a k -platelets. Platelets from the N a k -individuals adhered to types I, 111, and IV collagen in the presence of 2 mmol/L Mg++ to the same or to a slightly greater extent than did normal platelets at all time points, from 4 to 60 minutes ( P z 0.1; Fig 2) . In the presence of 100 pM EDTA, normal and NaY-platelet adhesion was decreased at all time points compared with adhesion in the presence of Mg++; however, no significant differences were observed in adherence between normal and Naka-platelets at any time ( P 2 .05). In the experiments using type I collagen with Naka-platelets n = 6, and with normal platelets n = 4; in experiments using types 111 or IV collagen with N&"-platelets n = 2, and with normal platelets n = 5.
The 176D7 antibody inhibited platelet adhesion to type I, type 111, and type IV collagen when added at concentrations of 0.2 to 20 &well with both normal and N e -platelets (Fig 3) . In the time course of adhesion, 176D7 was allowed to incubate with normal or Naka-platelets on type I collagencoated wells for 1 to 29 minutes. The 176D7 caused progressive inhibition of normal and N e -platelet adhesion from 1 to 29 minutes of incubation. There was no significant difference between normals (n = 6) and N e -platelets (n = 3) in the percentage of adhesion at any time point ( P 2 0.2; Fig 4) . No significant difference was noted in the amount of adhesion at any time point between normal and Napplatelets incubated with saline instead of antibody ( P 2 0.2).
By flow cytometry the mean number of positive cells with OKM5 in Naka-platelets was 2.0% compared with 97.0% in normals, and with 18568 was 2.2% compared with 98.4% in normals. However, monocytes from these two patients did express GPIV. The mean number of positive cells was 98.1% compared with 86.6% in normals. The N e -platelets had normal amounts of GPIb and GPIIb-IIIa by flow cytometry and of CY&, integrin by flow cytometry and concentrationdependent binding with the antibody 176D7 (Fig 5) . Nak"-platelets stimulated with ADP or thrombin expressed normal amounts of thrombospondin, von Willebrand factor, and fibrinogen on their cell surface.
Normal and Naka-platelets activated with thrombin showed no significant difference in the number of thrombospondin molecules detected by the MoAb antibody 181G8. Normal platelets expressed 30,800 molecules of thrombospondin per platelet with a dissociation constant (Kd) of 23 nmoliL. Nay-platelets expressed 30,400 molecules of thrombospondin with a Kd of 81 nmolL. Similar amounts of thrombospondin were detected on unstimulated or EGTAtreated normal andlor N e -platelets; approximately 3,000 thrombospondin molecules were detected per platelet.
Concentration-dependent binding of 185G8 or OKM5 to normal platelets in the presence of EGTA showed 49,500 sites per platelet with a Kd of 32 nmoliL. In contrast, the Nak"-platelets contained only 500 sites per platelet and a Kd of 2 nrnon. Thrombin activation of normal or Napplatelets did not alter the number of sites expressed or the Kd.
Perfusion studies of platelet adhesion at high shear rates showed no significant differences between Naka-platelets and normal platelets in the number of contact or spread platelets. Examination of the vessel segments showed about 30% of the subendothelial surface to be covered with platelets with the majority of this coverage composed of a mono- For personal use only. on October 22, 2017. by guest www.bloodjournal.org From layer of spread platelets. Less than 3% of the surface was covered by platelets that had contacted the surface but had not spread, and less than 1% of the surface was occupied by platelet thrombi.
DISCUSSION
We have studied two N&"-Japanese women whose platelets contain 1% to 2% of GPIV who have not experienced any hemostatic problems. GPIV has been proposed as a receptor for platelet adhesion to collagen and as a collagen and thrombospondin binding site; however, in our studies which are in agreement with those of Kehrel et a1 and Tandon et al, stimulated platelets deficient in GPIV have the same capacity as normal platelets to bind endogenous thrombosp~ndin.~"~~ Collagen-induced platelet aggregation and ATP release were normal or enhanced in the individuals with GPIV deficiency, which has also been reported by Yamamoto et al.25 Perhaps, N W -platelets use alternative pathways for some platelet functions that, in the case of collagen-induced platelet aggregation, over compensates for their lack of GPIV. N e -platelets were indistinguishable from normal platelets in the extent of adherence to purified type I, 111, or IV collagen in the presence of Mg'+ or a low concentration of EDTA at all time points from 4 to 60 minutes. The a2PI integrin appears to be primarily responsible for platelet aggregation to collagen and static platelet adhesion to collagen in our system. Nak"-platelets had normal amounts of a2PI integrin and, accordingly, were inhibited by the anti-@, integrin 176D7 to the same extent as normal platelets in both platelet adhesion to collagen and in collagen-induced platelet aggregation. From these studies in individuals who lack GPIV, we cannot identify a specific role for GPIV in static platelet adhesion to collagen or high shear force platelet adhesion to the subendothelium.
In a recent publication, Diaz-Ricart et alZ5 have reported that platelets lacking CD36 showed significantly decreased adhesion to collagen in a flowing whole blood system at 2 and I O minutes of perfusion time. We have not performed time course experiments in our perfusion system, but there are several differences between our perfusion system and the perfusion system used by Diaz-Ricart et al. Our perfusions are perfornled at a shear rate of 2,600" seconds that approximates the shear force in arterioles or arteries with a high degree of stenosis. Their perfusions were performed at a shear rate of 800" seconds that more closely approximates the shear force in larger vessels such as veins and arteries. We used umbilical arterial segments in our system, whereas Diaz-Ricart et a1 used plastic coverslips coated with equine tendon collagen.
Perhaps, the differences in methods used also play a role in the discrepancies between our results in static adhesion and the results obtained by other investigators. For example, we labeled platelets with "'In as opposed to 5'Cr, and we used bovine collagen as opposed to equine collagen. The methods we have used have not provided us with evidence that GPIV plays a role in collagen-induced platelet aggregation, in platelet adhesion to collagen in either a static or high shear force system, or in the endogenous or exogenous thrombospondin binding to platelets. These studies do not exclude other role(s) for GPIV in other aspects of platelet physiology or pathology.
